AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection

Prescription Icon
Prescription Required

Marketer

Cipla Ltd

Salt Composition

Casirivimab (120mg) + Imdevimab (120mg)

Overview Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection

The 120mg/120mg Casirivimab and Imdevimab injection is a dual monoclonal antibody therapy for adults and children (12+ years, >40kg) with mild to moderate COVID-19. Optimal efficacy requires early administration (7-10 days post-diagnosis). Approved for emergency use by India's CDSCO on May 3rd, 2021, and subsequently authorized in the US, Switzerland, Germany, France, Italy, and other nations, this treatment is administered intravenously or subcutaneously by a healthcare professional, ideally in a hospital setting. Potential side effects, including severe allergic reactions (anaphylaxis), necessitate post-injection monitoring (at least 1 hour). Common adverse reactions include injection site inflammation, fever, facial flushing, respiratory distress, chest constriction, nausea, and vomiting; report any such symptoms immediately. Prior medical conditions, concurrent medications, and pregnancy/breastfeeding status should be disclosed to your physician before treatment. For assistance locating this medication or treatment, please [link/contact information].

Uses of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection

Managing mild to moderate cases of COVID-19

Major Benefits of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection:

Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.

Common Side effects of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection:

  • Injection site reactions (pain, swelling, redness)
  • Fever
  • Flushing (sense of warmth in the face, ears, neck and trunk)
  • Breathlessness
  • Chest tightness
  • Nausea
  • Vomiting

How to use Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection:

The medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.

How Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection works:

A dual monoclonal antibody injection, Casirivimab and Imdevimab (120mg/120mg), employs two distinct human IgG1 antibodies targeting separate sites on the SARS-CoV-2 spike protein. This recombinant DNA-engineered approach ensures broad effectiveness against current and future COVID-19 variants by blocking viral entry into human cells.

SAFETY ADVICE

AlcoholAlcoholCONSULT YOUR DOCTOR

The interaction between alcohol and the Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection is undetermined. Seek medical advice before combining them.

PregnancyPregnancyCONSULT YOUR DOCTOR

Data on the use of the Casirivimab and Imdevimab 120mg/120mg injection combination during pregnancy is lacking. Seek medical advice from your physician.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Data on the use of the Casirivimab and Imdevimab combination injection (120mg/120mg) while breastfeeding is currently lacking. Seek medical advice from your physician.

DrivingDrivingSAFE

The combined injection of casirivimab and imdevimab (120mg/120mg) typically has no impact on driving ability.

KidneyKidneySAFE IF PRESCRIBED

The combined Casirivimab and Imdevimab injection (120mg/120mg) appears safe for individuals with kidney disease. Preliminary findings indicate dose modification may be unnecessary for this population. Physician consultation is advised.

LiverLiverCONSULT YOUR DOCTOR

Data regarding the application of the Casirivimab and Imdevimab 120mg/120mg injection in individuals with hepatic impairment is scarce. Physician consultation is recommended.

What if you forget to take Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection :

Should you forget a dose of the Casirivimab and Imdevimab 120mg/120mg injection, seek medical advice.

Facts to Know About Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection

LabelValue
Developing Habits No.

FAQs on Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection

Monoclonal antibodies are targeted proteins that act like the immune system, neutralizing harmful microbes such as viruses. The Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection uses these antibodies—casirivimab and imdevimab—to help protect against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19.
A monoclonal antibody cocktail combines individually available monoclonal antibodies for simultaneous administration.
The COVID-19 virus, SARS-CoV-2, uses a surface spike protein to invade human cells. Monoclonal antibody therapy works by blocking this interaction, thus hindering infection. Early treatment with monoclonal antibodies may alleviate mild symptoms.
COVID-19 monoclonal antibody therapy is indicated for individuals 12 years and older weighing at least 40 kg, following early diagnosis. High-risk patients, including those 60 and older, with comorbidities like diabetes or hypertension, or those immunocompromised, may also benefit.
COVID-19 monoclonal antibody treatment is unsuitable for hospitalized individuals or those requiring oxygen therapy, including those using oxygen due to pre-existing conditions unrelated to COVID-19. This treatment should also be avoided by anyone allergic to Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection or its components.
Older adults (60+), obese individuals, and those with pre-existing lung, kidney (including dialysis patients), or liver conditions, or weakened immunity (such as cancer patients), face a significantly elevated risk of severe COVID-19.
Healthcare professionals administer the Casirivimab & Imdevimab 120mg/120mg injection intravenously or subcutaneously in a hospital setting to manage mild to moderate COVID-19 symptoms. Intramuscular injection is contraindicated.
Patients with high blood pressure or diabetes may receive Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection if their doctor prescribes it. Available data suggests the treatment's benefits outweigh potential risks.
Casirivimab & Imdevimab C...
98,088
MRP 1,19,500
17% off